Profil
Cole Ikkala is currently the Head of Business Operations for the Neuroscience Group at Radius Health, Inc. Prior to this, he worked as the Director of Investor Relations and Communications at NVN Liquidation, Inc.
Aktive Positionen von Cole Ikkala
| Unternehmen | Position | Beginn |
|---|---|---|
| RADIUS HEALTH, INC. | Corporate Officer/Principal | 01.07.2020 |
Ehemalige bekannte Positionen von Cole Ikkala
| Unternehmen | Position | Ende |
|---|---|---|
| NVN LIQUIDATION, INC. | Investor Relations Kontakt | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NVN LIQUIDATION, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
